Welcome to the e-CCO Library!

OP01: Withdrawal of infliximab or anti-metabolite therapy in Crohn’s Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE)
Year: 2022
Source: ECCO'22
Authors: LouisJ, E.(1);Resche-Rigon, M.(2);Laharie, D.(3);Satsangi, J.(4);Ding, N.(5);Preiss, J.(6);d'haens, G.(7);picon, L.(8);bossuyt, P.(9);vuitton, L.(10);irving, P.(11);bouhnik, Y.(12);viennot, S.(13);lamb, C.(14);pollock, R.(15);baert, F.(16);nachury, M.(17);mathurin, F.(18);Gilletta, C.(19);colombel, J.F.(20);hertervig, E.(21);
Created: Friday, 11 February 2022, 3:52 PM
OP02 Impact of therapeutic strategies on intestinal resection rate in paediatric inflammatory bowel diseases: A population-based cohort study over a 24-year period (1988–2011)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D. Ley1, A. Leroyer2, C. Dupont3, H. Sarter2, V. Bertrand4, C. Spyckerelle5, N. Guillon2, B. Pariente6, G. Savoye7, D. Turck1, C. Gower-Rousseau2, M. Fumery8, Epimad group

Created: Thursday, 30 January 2020, 10:12 AM
OP020: Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohns disease: interim analysis from the Phase 2 FITZROY study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Vermeire*1, S. Schreiber2, R. Petryka3, T. Kuehbacher4, X. Hebuterne5, X. Roblin6, M. Klopocka7, E. Goldis8, M. Wisniewska-Jarosinska9, A. Baranovsky10, R. Sike11, C. Tasset12, A. Van der Aa12, P. Harrison12

Created: Friday, 22 February 2019, 9:49 AM
OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Gils A.
Last Modified: Wednesday, 15 March 2017, 2:33 PM by ECCO Administrator
Therapeutic drug monitoring, Pharmacokinetics, Vedolizumab
Files: 1
OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gils A.*1, Dreesen E.1, Compernolle G.1, Peeters M.1, Brouwers E.1, Tops S.1, Ballet V.2, Noman M.2, Ferrante M.2, Van Assche G.2, Vermeire S.2

Created: Wednesday, 20 February 2019, 10:36 AM
OP020: The clinical determinants affect gut microbial profile of inflammatory bowel disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Juillerat1*, B. Yilmaz2, R. Wiest1,2, G. Rogler3, A.J. Macpherson1

Created: Thursday, 21 February 2019, 9:14 AM
OP021: Autologous haematopoietic stem cell transplantation for Crohn’s disease: a retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Brierley1*, C. Castilla-Llorente2, M. Labopin3, M. Badoglio3, M. Rovira4, E. Ricart5, D. Dierickx6, S. Vermeire7, P. Hasselblatt8, J. Finke9, F. Onida10, A. Cassinotti11, J. Satsangi12, M. Kazmi13, A. López-Sanromán14, D. Farge15, S. Travis16, C. Hawkey17, J. Snowden18

Created: Thursday, 21 February 2019, 9:14 AM
OP021: Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate-to-severe Crohns disease: results of a Phase 2b randomised placebo-controlled trial
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. D’Haens*1, R. Pannaccione2, P. D. R. Higgins3, J.-F. Colombel3, B. G. Feagan4, M. Moscariello5, G. Chan5, P. Healey6, W. Niezychowski5, W. Wang5, A. Marren5, E. Maller5

Created: Friday, 22 February 2019, 9:49 AM
OP021: Hyperbaric oxygen therapy is safe and effective for hospitalized ulcerative colitis patients suffering from moderate-severe flares: a multi-center, randomized, double-blind, sham-controlled trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Dulai P.*1,2, Buckey Jr. J.2, Raffals L.3, Swoger J.4, Claus P.3, O'Toole K.4, Ptak J.2, Gleeson M.2, Widjaja C.1, Adler J.2, Patel N.2, Skinner L.2, Haren S.3, Goldby-Reffner K.4, Thompson K.2, Knight R.1, Chang J.1, Siegel C.2

Created: Wednesday, 20 February 2019, 10:36 AM
OP022: Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate-to-severe Crohns disease: results of a Phase 2b randomised placebo-controlled trial
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. Panés*1, W. J. Sandborn2, S. Schreiber3, B. E. Sands4, S. Vermeire5, G. Chan6, M. Moscariello6, W. Wang6, W. Niezychowski6, A. Marren6, P. Healey7, E. Maller6

Created: Friday, 22 February 2019, 9:49 AM
OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Kalla R.
Last Modified: Wednesday, 15 March 2017, 2:30 PM by ECCO Administrator
Crohn's disease, Ulcerative colitis, Immunology
Files: 1
OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kalla R.*1, Adams A.1, Vatn S.2, Bergemalm D.3, Ricanek P.4, Lindstrom J.2, Ocklind A.5, Nordberg N.5, Kennedy N.1, Ventham N.1, Vatn M.4, Söderholm J.6, Pierik M.7, Törkvist L.8, Gomollόn F.9, Jahnsen J.2, Halfvarson J.3, Satsangi J.1 IBD Character Consortium, Edinburgh, United Kingdom

Created: Wednesday, 20 February 2019, 10:36 AM
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Schreiber1*, L. Peyrin-Biroulet2, B. Boland3, P.D. Higgins4, A. Armuzzi5, J. Terdiman6, W. Zhou7, G. Alperovich8, F. Cataldi7, S. Goteti7, A.P. Lacerda7

Created: Thursday, 21 February 2019, 9:14 AM
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study
Year: 2018
Source: ECCO'18 Vienna
Authors: Schreiber Stefan
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD)
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Danese1*, B. Feagan2, W. Sandborn3, J.-F. Colombel4, S. Vermeire5, S. Jones6, K. Brennan6, J. Bornstein7

Created: Thursday, 21 February 2019, 9:14 AM
OP023: Comparison between newly developed narrow band imaging and panchromoendoscopy for surveillance colonoscopy in patients with ulcerative colitis: a prospective multicentre randomised controlled trial, navigator study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

K. Watanabe*1, M. Nishishita2, F. Shimamoto3, T. Fukuchi4, M. Esaki5, Y. Okamoto5, Y. Maehata5, S. Oka6, S. Nishiyama6, S. Fujii7, F. Hirai8, T. Inoue9, N. Hida10, R. Nozaki11, T. Sakurai12, K. Takeuchi13, M. Saruta14, S. Saito15, Y. Saito16, N. Ohmiya17, H. Kashida12, S. Tanaka6, T. Matsui8, Y. Suzuki18, Y. Ajioka19, H. Tajiri20

Created: Friday, 22 February 2019, 9:49 AM
OP023: Maintenance of clinical effect in patients with moderate- to-severe Crohn’s Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Vermeire S.
Last Modified: Wednesday, 15 March 2017, 2:28 PM by ECCO Administrator
Filgotinib
Files: 1